CD274 and non-small cell lung carcinoma: With its unique “tumorimmunity + antiangiogenesis” dual‐targlkhfsaet synergistic antitumor mechanism, AK112 is expected to bring new hope to NSCLC patients who are drug‐resistant after PD‐1/PD‐L1 inhibitor therapy.